These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30522875)

  • 1. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
    Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
    Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
    Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
    Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
    J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
    Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
    JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
    Hamuro A; Honda M; Wakaura Y
    Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
    [No Abstract]   [Full Text] [Related]  

  • 17. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.